Pemvidutide official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
MOMENTUM studied weight over 48 weeks
NCT05295875 records 391 participants in a randomized, blinded, placebo-controlled obesity study. Its primary endpoint is relative percentage change in body weight at week 48; metabolic measures and adverse events appear separately. NCT05295875 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
IMPACT asks a liver-disease question
NCT05989711 records 212 participants in a separate placebo-controlled study of non-cirrhotic steatohepatitis. Its primary endpoints include 24-week histological resolution without fibrosis worsening and fibrosis improvement without disease worsening. NCT05989711 ↗
Liver biopsy and imaging endpoints should remain distinct
IMPACT lists MRI-measured liver fat as a secondary outcome alongside the biopsy-based primary endpoints. Less liver fat on imaging is not, by itself, the same finding as improved fibrosis or fewer clinical liver complications. NCT05989711 ↗
Completed records still need a separate results source
Both records are marked completed, but neither retrieved payload contains posted summary results. The last-posted updates are November 29, 2023 for MOMENTUM and May 18, 2026 for IMPACT; publications must be matched and appraised separately. NCT05295875 ↗NCT05989711 ↗
What remains to be checked
- Retrieve and appraise MOMENTUM and IMPACT results with their original protocols and analysis plans.
- Keep weight, biopsy-based liver outcomes and imaging measures distinct; exclude unrelated drugs sharing the ALT-801 code.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Efficacy and Safety of ALT-801 in the Treatment of Obesity ↗
Source dated 2023-11-29; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.outcomesModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
8df524b208735c78d68b871c884de78d0354ddbaf2cede1f07ed1932c0eabbcfIMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) ↗
Source dated 2026-05-18; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.outcomesModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
479c36b141fd86c8fae6746a1bc773861ad9f2788575ad5828b2e74885222bb0